Hikma Pharmaceuticals is deepening its roots in Ohio with a $267 million dual-city expansion that will add 350 new jobs and substantially increase the company’s domestic capacity to produce and supply critical generic medicines. Announced on 1 June 2026 alongside Ohio Governor Mike DeWine and backed by a coalition of state and local economic development partners, the investment spans two of the UK-listed company’s existing Ohio operations. In Bedford, northeast Ohio, a $51 million commitment will expand injectable pharmaceutical manufacturing at a facility on Northfield Road that has operated as a pharmaceutical site since 1938, adding advanced aseptic vial filling and lyophilization capabilities alongside IV bag production, warehousing, and distribution. Up to 300 new jobs will be created at that location. In Columbus, a far larger $216 million outlay will grow oral solid dose and nasal inhalation manufacturing operations, generating 50 additional positions at a plant that already employs more than 1,200 people and serves as the largest manufacturing employer in the City of Columbus. Columbus is also one of only three global R&D hubs in Hikma’s worldwide network. The investment is part of the company’s broader $1 billion strategic commitment to domestic pharmaceutical manufacturing announced in June 2025, and is subject to finalisation of economic development incentives from JobsOhio and several county and city financing authorities.

Ohio’s Pharma Momentum Becomes Impossible to Ignore

Hikma’s announcement lands in an Ohio that is rapidly maturing into one of the United States’ foremost pharmaceutical manufacturing corridors, and this expansion cements the state’s position rather than simply adding to it. Over the past 15 years, Hikma alone has invested nearly $5 billion in its U.S. manufacturing, R&D, and distribution infrastructure, with Ohio serving as the undisputed heart of those operations. The state is currently ranked seventh in the country for biotech human capital and workforce, and JobsOhio has been actively cultivating that pipeline through the Ohio Discovery Corridor and a new biomanufacturing workforce training initiative centred in the Columbus area, designed to produce work-ready technicians and operators for exactly the kind of facility Hikma is now expanding. Amgen’s parallel $900 million expansion of its New Albany facility, bringing its total central Ohio commitment past $1.4 billion, underscores how companies view the region as structurally favourable for large-scale life sciences manufacturing. The pattern is also visible elsewhere in the U.S. sunbelt: Lupin Ltd.’s recently announced $250 million respiratory manufacturing facility in Coral Springs, Florida follows a near-identical logic of domestic onshoring, targeted job creation, and state incentive partnerships. What distinguishes Ohio is the sheer concentration of investment and the depth of existing industrial infrastructure, both of which make each successive announcement more credible than the last.

Project Fact Sheet

• Project Name: Hikma Pharmaceuticals Ohio Manufacturing Expansion
• Locations: Bedford (Northfield Road), Northeast Ohio and Columbus, Central Ohio
• Project Value: $267 million total ($51 million in Bedford; $216 million in Columbus)
• Client / Owner: Hikma Pharmaceuticals PLC (LSE: HIK)
• Scope in Bedford: Advanced aseptic vial filling, lyophilization, IV bag production, warehousing and distribution
• Scope in Columbus: Oral solid dose and nasal inhalation manufacturing expansion; R&D hub operations
• Jobs Created: 350 total (up to 300 in Bedford; 50 in Columbus)
• Construction Start: Pending finalisation of economic development incentives
• Strategic Context: Part of Hikma’s $1 billion domestic manufacturing commitment announced June 2025
• Annual Production Capacity: More than 12 billion finished doses across Hikma’s Ohio and New Jersey operations
• Incentive Partners: JobsOhio, City of Bedford, City of Columbus, Cuyahoga County, Franklin County Finance Authority, Cuyahoga County/Cleveland Finance Authority
• Workforce Initiative: Proximity to Ohio Discovery Corridor biomanufacturing training hub (Columbus area)

Project Team

• Client / Owner: Hikma Pharmaceuticals PLC, headquartered in London, UK
• Ohio Economic Development Lead: JobsOhio (J.P. Nauseef, President and CEO)
• Regional Partners: Team NEO (Northeast Ohio); One Columbus / Columbus Partnership (Central Ohio)
• State Government: Office of Ohio Governor Mike DeWine
• Local Government Partners: City of Bedford (Mayor Stanley C. Koci); City of Columbus (Mayor Andrew J. Ginther)
• Financing Authorities: Franklin County Finance Authority; Cuyahoga County/Cleveland Finance Authority
• Main Contractor: Expected to be selected from regional and national general contractors with pharmaceutical manufacturing experience, likely including firms such as Turner Construction, Skanska, or McCarthy Building Companies
• Design / Engineering: Likely specialist pharmaceutical facility engineers; firms such as CRB Group or HDR have active portfolios in Ohio life sciences construction